



Company Contact - Jim Dorsey
BioClinica
267-757-3040

Media Contact – Beth Nestlerode
Diccicco Battista Communications
484-342-3600

Investor Contact - Linda Decker
Financial Media - Bill Gordon
Porter, LeVay & Rose, Inc.
212-564-4700

FOR IMMEDIATE RELEASE

BIOCLINICA INTRODUCES NEW REPORTING SOLUTION THAT SUPPORTS METRICS CHAMPION CONSORTIUM CLINICAL TRIAL PERFORMANCE METRICS

- Extends Standardized Performance Reporting Across Clinical Trials –

-To Be Demonstrated at DIA Annual Meeting Through June 16 in Washington, D.C.-

NEWTOWN, PA, June 15, 2010 – BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, is the first clinical technology provider to offer a reporting solution that incorporates the industry-standard performance metrics for clinical trials as defined by the Metrics Champion Consortium (MCC).

BioClinica is a Corporate Sponsor of the Metrics Champion Consortium (MCC), an open, collaborative organization dedicated to fostering the development of performance metrics for both Sponsors and Service Providers in support of an improved drug development process. BioClinica has supported the definition of both Imaging and Clinical Trials metrics through its participation in the MCC. “BioClinica is a vigorous supporter of standards initiatives such as the MCC and CDISC. Standards help the industry drive efficiency and facilitate transparency of the data associated with clinical trials,” said Peter Benton, President of BioClinica’s eClinical Division.

The Clinical Trial Performance Metrics allow trial sponsors and CROs to share a common view of clinical trial performance across studies. “As we approach the release of MCC Clinical Trial Performance Metrics version 1.0, we are pleased by the enthusiasm of MCC members preparing to be able to track and report the metrics. The BioClinica reporting system is a good example of how MCC members are helping us move forward with fulfilling our mission of providing the platforms, tools and shared learning opportunities that encourage performance improvement, effectiveness, efficiency and appropriate levels of control in the drug development process” states Guy Mascaro, President of the MCC.

The BioClinica Performance Dashboard and portals provide MCC-Based Metrics/Scorecards such as:

- Patient Retention
- Generation of Query to update of Query Response
- CRF Pages Received/scanned to Data Entry Complete
- Site Productivity
- % subjects enrolled, and
- Site Activation to First Patient First Visit

-more-

The MCC Clinical Trial Performance Metrics (beta version), was released for industry review in April. BioClinica will demonstrate the first instance of MCC Clinical Trial Performance metrics that have been programmatically generated across studies and from different clinical systems. The reports deliver data on study progress with interactive functionality that allows users to drill down on various aspects of tracking performance. This reporting solution is part of the BioClinica Integrated Operational Platform demonstration at the 46th DIA Annual Meeting in Washington, DC at exhibits #111 and #2005 from June 14 - 16.

Follow BioClinica on the *Trial Blazers* blog at <http://info.bioclinica.com/blog>, and on twitter at <http://twitter.com/bioclinica>.

About BioClinica, Inc.

BioClinica, Inc. is a global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transfer, electronic data capture, interactive voice and web response, clinical trial management, and clinical supply chain forecasting and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

#####